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Background: This study was conducted in Kassala Teaching Hospital, Kassala State, Sudan
(January 2006–June 2008) to determine the rate of mycobacterium drug resistance to
anti-tuberculous treatment and to explore the genotype of Mycobacterium tuberculosis
resistant isolates using rpoB gene.
Methods: 53 isolates of mycobacterium isolated from pulmonary tuberculosis (PTB) patients
from Kassala State were subjected to drug susceptibility testing (DST) to anti-tuberculous
drugs; 10 M. tuberculosis complex (MTBC) resistant isolates were subjected to polymerase
chain reaction (PCR), and commercially the amplified DNA was sequenced.
Results: DST detected resistance in 23/53 (43.39%) isolates, among which rifampicin had a
high number of resistant isolates (13/23), followed by streptomycin (11/23), and multi-drug
resistance was detected in 5 isolates.
DNA sequence analysis of 10 MTBC-resistant isolates detected variations within and out-
side the rifampicin resistant determining region (RRDR). Variation within RRDR was
detected at positions 512 (AGC/ATC, Ser/Ile), and 528 (CGC/CTC, Arg/Leu). Outside the RRDR
region variations were detected at positions 498 (GTG/GGG, Val/gly), 488 (ACA/ACC, Thr/
Thr), which is a silent mutation. Insertions were observed at positions 484, 496 (GTG/GTGA,
CGG/CAGG, respectively). Deletion was observed at position 487 (ATC/_TC).
Discussion and conclusion: This study revealed that high resistance to rifampicin was asso-
ciated with various point mutations in and out of the RRDR of the rpoB gene. Molecular
methods are needed for early detection of TB disease and drug resistance.
 2015 Asian African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.Introduction
Tuberculosis (TB) is a curable disease, though it still remains a
major public health problem worldwide, especially in devel-
oping countries. Globally, it ranks as the second leading causeof death from an infectious disease. In 2012, the estimated
new cases were 9.0 million and 1.5 million TB deaths [1].
The situation has become alarming due to dual infection with
HIV and the development of drug resistance. The emergence
of resistance to drugs used for TB treatment, and particularly
Table 1 – Sensitivity test of the MTB isolates to first line anti-
tuberculous drugs.
Drug susceptibility No. of isolates %
Sensitive 30 56.6
Resistance to one drug 12 22.64
Resistance to two drugs 7 13.2
Resistance to three drugs 4 7.5
Total 53 100
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public health problem in a number of countries and an obsta-
cle to effective global TB control [2]. Globally, 3.6% of new TB
cases and 20.2% of previously treated cases are estimated to
have MDR-TB [3]. Both Rifampin (RIF) and Isoniazid (INH)
resistance are reliable markers of MDR-TB [4]. Resistance to
RIF is caused by mutations in the b subunit of RNA polymer-
ase, a target of RIF, which is encoded by the rpoB gene. More
than 95% of the resistant strains harbor mutations within
an 81-bp hot-spot region (codons 507–533) of rpoB, named
RIF resistant determining region (RRDR) [5]. In contrast, INH
resistance is due to a mutation at one of two main sites, in
either katG or inhA genes [6].
High incidence ranks Sudan among the high prevalence
countries for TB in the Eastern Mediterranean region and
accounts for 14.6% of the total TB burden [7]. No clear data on
MDR-TB was reported in Sudan. A few studies have reported
the detection of drug resistance in some States [8]. This study
was initiated to determine the rate of mycobacterium drug
resistance to anti-tuberculous treatment and to explore the
genotype of MTB-resistant isolates using rpoB gene.
Methods
Study design and sample collection
This is a descriptive cross-sectional study. It was conducted at
the Chest Department, Kassala Teaching Hospital, Kassala
State, Sudan during the period from 2007 to 2009. 113 of the
pulmonary TB cases that were subjected to treatment based
on the laboratory diagnosis and/or clinical symptoms and
X-ray findings were enrolled in the present study. Each
patient was requested to give an adequate sputum sample
in a specific container for culture and DST.
Culture and DST
200 lL from each of the digested and decontaminated sputum
samples was inoculated in Lowenstein Jensen (LJ) medium. A
subculture was prepared for the successful growth samples
followed by DST, which was done for 53 clinical isolates of
mycobacterium using the proportion method described by
Sethi et al. [9]. Briefly, the LJ medium with each drug incorpo-
rated in various concentrations (0.2 lg/mL for INH, 40 lg/mL
for RIF, 4 lg/mL for streptomycin [SM] and 2.0 lg/mL for Eth-
ambutol [ETH]) and a plain medium for control were pre-
pared. The bacterial serial dilution suspensions (102 and
104) were inoculated in the prepared media, and then incu-
bated at 37 C. The readings of the incubated samples were
taken after 28 days, and the second one was taken after
42 days. The resistance was calculated as the ratio of the
number of colonies on the drug-containing medium and
those of the control media. The isolate was considered as
resistant if the ratio was greater or equal to 1% [9].
DNA extraction, amplification and sequencing
DNA was extracted by boiling method as described by Khos-
ravi [10]; 2–5 loops-full of mycobacterial colonies were har-
vested in 500 lL double-distilled water in sterile Eppendorftube, boiled in a water bath at 100 C for 10 min, then centri-
fuged at 13,000 rpm for 5 min, the supernatant was collected
in a sterile Eppendorf tube and stored at 20 C until used as a
template for PCR. Amplification of the product was done as
described by Kim [11] using the primer:
tbc1 5 0-CGT ACG GTC GGC GAG CTG ATC CAA-3.
tbcR 5-CCG ACA GTC GGC GCT TGT GGG TCA-3 0.
The amplified DNA of 10 resistant isolates of MTBC was
commercially sequenced (Macro GEN Company, Seoul, South
Korea) to detect the change of DNA sequences. The result of
MTBC-resistant isolate sequences were aligned with the rpoB
gene sequence of MTB H37RV strain by using Blast (http://
WWW//ncbiblast).
Results
The DST showed that 30 (56.6%) isolates were sensitive to the
minimum concentration of the drugs, while 23 (45.3%) were
resistant to at least one anti-tuberculous drug. The resistance
varied from single 12 (52.17%), double 6 (26.08%), to multi-
drug resistance 5 (21.74%) as shown in Table 1. RIF revealed
the highest resistance pattern in combination with other
drugs 13 (56.53%). Among the resistant isolates, 10 (43.47%)
were sensitive to RIF.
DNA sequence analysis of 10 isolates showed no change in
5 (50%) isolates, while the others had different types of muta-
tions. Mutations included substitution, deletion and insertion
of nucleotides within and out of RRDR.
Single change was demonstrated in resistant isolates at
512 (AGC/ATC, Ser/Ile), and 475 (GTC/GGC, Val/Gly). Deletion
at 487 (ATC/_TC) was observed in a susceptible isolate, but
resistant to SM and ETH. Insertion was in site 496 (CGG/
CAGG). In other isolates more than one change was observed
at 528 (CGC/CTC, Arg/Leu), 498 (GTG/GGG, Val/Gly), and 488
(ACA/ACC, Thr/Thr) (Table 2).
From the above result, only two variations were demon-
strated at RRDR, and the remaining variations were outside
that region. No variation was detected in four resistant iso-
lates, among which one was RIF resistant, two were resistant
to INH and the fourth was SM resistant.
Discussion
Resistance to anti-tuberculous drugs is an emerging global
health problem [12]. Spread of multidrug-resistant strains of
MTB has become a major public health concern in both devel-
Table 2 – Detected DNA sequence variations in MTBC resistant isolates.
Isolate number Drug susceptibility Codon number Mutated bases Type of mutation Change in amino acid
1 Resistant 512 AGC/ATC Substitution Serine/Isoleucine
2 Resistant 496 CGG/CAGG Insertion
3 Resistant 475 GTC/GGC Substitution Valine/Glycine
4 Resistant 528 CGC/CTC Substitution Arginine/Leucine
498 GTG/GGG Substitution Valine/Glycine
488 ACA/ACC Silent Threonine/Threonine
5 Sensitive 487 ATC/_TC Deletion
6 Resistant No change
7 Sensitive No change
8 Sensitive No change
9 Sensitive No change
10 Sensitive No change –
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tance to first-line anti-tuberculous drugs in 23 (45.3%) out of
53 tested isolates. This may be due to inadequate therapy or
poor drug absorption [13]. Drug resistance was reported in
Sudan [14].
RIF is an effective anti-TB therapy and is the key compo-
nent of the short course of multi-drug therapy. Resistance
to RIF predicts resistance to INH and serves as a marker of
multi-drug resistance. In this study a high number of resis-
tant isolates to RIF was observed (56.5%), unlike the result
reported by Chand et al. [15] who reported high resistant iso-
lates to SM. MDR resistance was observed in 21.74% of cases
raising a major concern about future management of TB
patients in Sudan.
RIF resistance in MTB is associated with mutations in the
rpoB gene; it has been demonstrated in a genetic study that
more than 95% of resistance is due to mutations in the rpoB
gene [16]. Highly conservative rpoB genes play an essential
role in the physiology of MTB. DNA sequence studies indicate
that more than 96% of the RIF-resistant MTB had mutations
within the 81-bp hot spot region of the rpoB gene (RRDR)
corresponding to codons 507–533 [17]. In this study DNA
mutations were observed within and outside the RRDR region
of the rpoB gene in 5 isolates identified as resistant to anti-
tuberculous drugs. Within the RRDR region, DNA mutations
were detected at 512 (AGC/ATC, Ser/Ile) and 528 (CGC/CTC,
Arg/Leu). The mutations outside the RRDR of the rpoB of this
region were detected at different sites, including 498
(GTG/GGG, Val/Gly) 488 (ACA/ACC, Thr/Thr), which is a silent
mutation. Ramasoota [18]) reported the same result from the
study conducted in Thailand, and also reported a silent
mutation at the 488 codon. Deletions and insertions, which
were observed in two clinical isolates, resulted in a frame
shift and a formation of a truncated and non-functional
protein [19]. No mutations were observed in 5 isolates, among
which only 1 was RIF resistant and the others were resistant
to other anti-tuberculous drugs; these findings were in
agreement with the results reported in the study conducted
in the Russian Federation [20], in Turkey [21], and in China
[22] and in Japan [17].
The mutation at 528 was reported in the study conducted
in Pakistan and at 512 where a double mutation was reported
[23].Conclusion and recommendation
This study revealed that high resistance to RIF was associated
with various point mutations inside and outside of the RRDR
of the rpoB gene. Molecular methods are needed for early
detection of TB disease and drug resistance. The study of
adequate sample size from different sites in Sudan is needed
to reflect the clear picture of drug resistance in Sudan.
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